Back
Open Access

Prevalence and clinical implications of conduction system disease in patients with cardiac transthyretin amyloidosis

Session: Treatment considerations in amyloidosis
Topic: Clinical
Speaker: Doctor L. Schlender (Frankfurt, DE)
Event: Heart Failure 2025

Congress Presentation

Add to my library

Like

About the speaker

Doctor Lara Sophie Schlender

University Hospital Frankfurt, Frankfurt (Germany)
1 presentation
0 follower

6 more presentations in this session

Systematic screening for transthyretic cardiac amyloidosis in patients undergoing TAVI: results from a greek-cypriot registry

Speaker: Doctor T. Tsampras (Athens, GR)

Access
Abstract
Like
Thumbnail

Decoding the decades: Tafamidis efficacy across different age groups in ATTR-CM patients

Speaker: Doctor J. Fernandes Pedro (Lisbon, PT)

Access
Abstract
Like
Thumbnail

Exploring tafamidis outcomes across varying disease severities in ATTR-CM

Speaker: Doctor C. Gregorio (Lisbon, PT)

Access
Abstract
Like
Thumbnail

Tafamidis and patient-reported outcomes in ATTR cardiomyopathy

Speaker: Mr D. Ferreira (Lisbon, PT)

Access
Abstract
Like
Thumbnail

Autonomic disfunction and peripheral neuropathy assessment by TILT and EMG in cardiac amyloidosis: insights from a high-volume single center.

Speaker: Doctor R. Carvalho (Lisbon, PT)

Access
Abstract
Like
Thumbnail

Access the full session

Treatment considerations in amyloidosis

Speakers: Doctor L. Schlender, Doctor T. Tsampras, Doctor J. Fernandes Pedro, Doctor C. Gregorio, Mr D. Ferreira...
Access
Like
Thumbnail

About the event

Image

Heart Failure 2025

17 May - 20 May 2025

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Bristol Myers Squibb Explore sponsored resources
logo Novartis Explore sponsored resources
logo Novo Nordisk Explore sponsored resources